Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | MicrobiomeTrials← Back to trialsNCT06938867
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-04Est. Completion: 2027-10
Enrollment target: 66 participants Locations- City of Hope, Duarte, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- UPMC, Pittsburgh, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
Other microbiome trials you might be interested in
B Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…
Birmingham, United StatesEst. completion Dec 1, 2030
Recurrent B Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in t…
Birmingham, United StatesEst. completion Jun 30, 2021
Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with…
Birmingham, United StatesEst. completion Dec 31, 2028